Skip to main content
SpringerLink
Log in

Brodalumab

  • Chapter
  • First Online:
Advances in Psoriasis

  • 638 Accesses

Abstract

Brodalumab is a recombinant, fully human monoclonal receptor IgG2 antibody approved for the treatment of moderate-to-severe plaque psoriasis. It inhibits the IL-17 receptor A (IL-17RA), differing from other biologics in the IL-17 class which target the IL-17A cytokine itself. It is a highly effective medication, with a rapid onset of action. Its superiority to placebo and to ustekinumab has been shown in clinical trials, reducing both the severity and the extent of psoriasis, with efficacy sustained up to 52 weeks. It has also shown superiority to placebo in patients with difficult-to-treat nail and scalp psoriasis and early evidence of efficacy in patients with psoriatic arthritis. Brodalumab is generally well-tolerated with a safety profile similar to that of other biologics, with the addition of a label warning relating to suicidal ideation. Herein, we review the data behind the use of brodalumab for the treatment of psoriasis and psoriatic arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev. 2010;21(6):435–41.

    Article  CAS  PubMed  Google Scholar 

  3. Roostaeyan O, Kivelevitch D, Menter A. A review article on brodalumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy. 2017;9(12):963–78.

    Article  CAS  PubMed  Google Scholar 

  4. Hugh JM, Weinberg JM. Update on the pathophysiology of psoriasis. Cutis. 2018;102(5S):6–12.

    PubMed  Google Scholar 

  5. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Roman M, Chiu M. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of the IL-17 family members. Immunity. 2011;34(2):149–62.

    Article  CAS  PubMed  Google Scholar 

  8. Numaski M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101(7):2620–7.

    Article  CAS  Google Scholar 

  9. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50.

    Article  CAS  PubMed  Google Scholar 

  10. Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009;10:201–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet. 2010;42:991–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Georgescu SR, Tampa M, Caruntu C, Sarbu MI, et al. Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci. 2019;20(3):739.

    Article  CAS  PubMed Central  Google Scholar 

  13. Patel D, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43(6):1040–51.

    Article  CAS  PubMed  Google Scholar 

  14. Li J, Li D, Tan Z. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhnog Univ Sci Technolog Med Sci. 2004;24:294–6.

    Article  CAS  Google Scholar 

  15. Teunissen MB, Koomen CW, de Waal MR, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645–9.

    Article  CAS  PubMed  Google Scholar 

  16. Canavan TN, Elmets CA, Cantrell WL, et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17(1):33–47.

    Article  PubMed  Google Scholar 

  17. Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today. 2017;53(5):283–97.

    Article  CAS  Google Scholar 

  18. Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptory antibody for psoriasis. N Engl J Med. 2012;366:1181–9.

    Article  CAS  PubMed  Google Scholar 

  19. Russell C, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol. 2010;130:S46.

    Google Scholar 

  20. Russell C, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG827 leads to rapid reversal of gene expression and histopathologic abnormalities in psoriatic skin, including substantial pathway-specific effects within one week. J Invest Dermatol. 2011;131:S11.

    Article  CAS  Google Scholar 

  21. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–24.

    Article  CAS  PubMed  Google Scholar 

  22. Senra L, Stalder R, Alvarez Martinez D, Chizzolini C, et al. Keratinocyte-derived IL-17E contributes to inflammation in psoriasis. J Invest Dermatol. 2016;136(10):1970–80.

    Article  CAS  PubMed  Google Scholar 

  23. Rickel EA, Siegel LA, Yoon BR, Rottman JB, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol. 2008;181(6):4299–310.

    Article  CAS  PubMed  Google Scholar 

  24. Johnston A, Fritz Y, Dawes SM, Diaconu D, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–62.

    Article  CAS  PubMed  Google Scholar 

  25. Malakouti M, Brown GE, Wang E, Koo J, Levin EC. The role of IL-17 in psoriasis. J Dermatolog Treat. 2015;26(1):41–4.

    Article  CAS  PubMed  Google Scholar 

  26. Cosentyx (secukinumab) [package insert]. Switzerland: Novartis Pharmaceutical Corporation. 2016.

    Google Scholar 

  27. Taltz™ (ixekizumab) [package insert]. FDA: Eli Lilly and Company, Indianapolis, IN. 2016.

    Google Scholar 

  28. Siliq™ (brodalumab) [package insert]. Bridgewater: Valeant Pharmaceuticals North America LLC, NJ. 2017.

    Google Scholar 

  29. Papp K, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86.

    Article  CAS  PubMed  Google Scholar 

  30. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.

    Article  CAS  PubMed  Google Scholar 

  31. Blair H. Brodalumab: a review in moderate to severe plaque psoriasis. Drugs. 2018;78:495–504.

    Article  CAS  PubMed  Google Scholar 

  32. Golbari NM, Zito PM. Brodalumab. [Updated 2019 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470324/. Accessed May 2019.

  33. European Medicines Agency. Summary of product characteristics: Kyntheum 210mg solution for injection in pre-filled syringe. 2017. http://www.ema.europa.eu. Accessed May 2019.

  34. Salinger DH, Endres CJ, Martin DA, et al. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in first-in-human single ascending dose study. Clin Pharmacol Drug Dev. 2014;3(4):276–83.

    Article  CAS  PubMed  Google Scholar 

  35. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate-to-severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–9.

    Article  CAS  PubMed  Google Scholar 

  36. Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–36.

    Article  CAS  PubMed  Google Scholar 

  37. Osamu N, Hirotaka N, Koji S, Kenji T. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate-to-severe psoriasis: a randomized, dose-escalation, placebo-controlled study. J Dermatol Sci. 2014;75(3):201–4.

    Article  CAS  PubMed  Google Scholar 

  38. Kivelevitch D, Menter A. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. Immunotherapy. 2015;7(4):323–33.

    Article  CAS  PubMed  Google Scholar 

  39. Papp K, Menter A, Leonardi C. Improvement of psoriasis in subjects with and without previous brodalumab (AMG827) treatment in an open-label extension study. J Am Acad Dermatol. 2013;68(4):AB203.

    Google Scholar 

  40. Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized, controlled study. J Dermatol Sci. 2016;81(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  41. Umezawa Y, Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study Group. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):1957–60.

    CAS  PubMed  Google Scholar 

  42. Schadler ED, Ortel B, Mehlis S. Biologics for the primary care physician: review and treatment of psoriasis. Dis Mon. 2019;65:51–90.

    Article  PubMed  Google Scholar 

  43. Gottlieb A, Gordon K, Hsu S, Elewski B, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(8):1305–13.

    Article  CAS  PubMed  Google Scholar 

  44. Viswanathan H, Mutebi A, Milmont C, Gordon K. Measurement properties of the psoriasis symptom inventory electronic daily diary in patients with moderate to severe plaque psoriasis. Value Health. 2017;20:1174–9.

    Article  PubMed  Google Scholar 

  45. Papp K, Leonardi C, Paul C. AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis. Br J Dermatol. 2014;171(6):e119–20.

    Google Scholar 

  46. Yamauchi P, Papp K, Hsu S, Gottlieb A, et al. Improvement in scalp psoriasis with brodalumab in a randomized placebo-controlled phase 3 study (AMAGINE-1). J Am Acad Dermatol. 2017;76(6):AB408. [abstract no. 5247]

    Google Scholar 

  47. Conti HR, Shen F, Nayyar N, et al. Th17 cells and Il-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Strober B, Papp KA, Lebwhol M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77e77–82e77.

    Article  Google Scholar 

  51. Amgen and Astra Zeneca announce positive results from phase 3 study of brodalumab (AMG827) in patients with moderate-to-severe plaque psoriasis. 2014. http://www.amgen.com. Accessed May 2019.

  52. Amgen and Astra Zeneca announce positive results from second pivotal phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis. 2014. http://www.ext.amgen.com. Accessed May 2019.

  53. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183–90.

    Article  CAS  PubMed  Google Scholar 

  54. Sawyer LM, Cornic L, Levin LA, et al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2013;24(5):356–60.

    Google Scholar 

  55. Mease PJ, Genovese MC, Greenwald MW. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–306.

    Article  PubMed  CAS  Google Scholar 

  56. Lebwhol MG, Green L, Hsu S, et al. Improvement of nail psoriasis with brodalumab in phase 3 trials. J Am Acad Dermatol. 2017;76(6 Suppl 1):AB410. [abstract no. 5296]

    Google Scholar 

  57. Yilmaz SB, Cicek N, Coskun M, Yequin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465–9.

    Article  CAS  PubMed  Google Scholar 

  58. Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomized controlled trial. J Eur Acad Dermatol Venereol. 2014;28:1298–305.

    Article  CAS  PubMed  Google Scholar 

  59. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845–7.

    Article  CAS  PubMed  Google Scholar 

  60. Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28(4):538–359.

    Article  PubMed  Google Scholar 

  61. Pinter A, Wilsmann-Theis D, Peitsch WK, Mossner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol. 2019;46(5):426–30.

    Article  PubMed  Google Scholar 

  62. Mrowietz U, Moller AH, Hansen JB, et al. Treatment with brodalumab leads to significant improvements in patients’ daily lives compared with placebo [abstract no. P1792 plus poster]. In: 26th European Academy of Dermatology and Venerology Congress. 2017.

    Google Scholar 

  63. Armstrong A, Elewski B, Rastogi S, et al. Impact of brodalumab on work productivity in patients with moderate-to-severe plaque psoriasis: analysis of two phase 3 studies [abstract no. 6897 plus poster]. In: 76th Annual Meeting of the American Academy of Dermatology. 2018.

    Google Scholar 

  64. Papp K, Reich K, Paul C, et al. Improvements in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;74(5):AB254. [abstract no. 2863]

    Article  CAS  Google Scholar 

  65. Menter A, Strober B, Kaplan D, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

    Article  PubMed  Google Scholar 

  66. Green L, Hsu S, Papp K, et al. Fungal infections in patients with psoriasis during treatment with brodalumab: analysis of clinical trials [abstract no. 6839 plus poster]. In: 76th Annual Meeting of the American Academy of Dermatology. 2018.

    Google Scholar 

  67. Lebwhol MG, Papp KA, Marangelli LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–9.e5.

    Article  CAS  Google Scholar 

  68. Beck K, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19(4):287–92.

    Article  PubMed  Google Scholar 

  69. Chiricozzi A, Romanelli M, Saraceno R, Torres T. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15(12):1653–9.

    Article  CAS  PubMed  Google Scholar 

  70. Gooderham M, Gavino-Velasco J, Clifford C, MacPherson A, Krasnoshtein F, Papp K. A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20:293–303.

    Article  CAS  PubMed  Google Scholar 

  71. Singh S, Taylor C, Kornmehl H, Armstong A. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–40.e2.

    Article  PubMed  Google Scholar 

  72. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5.

    PubMed  PubMed Central  Google Scholar 

  74. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–51.

    Article  CAS  PubMed  Google Scholar 

  75. Leonardi C, Matheson R, Zachariae C. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;336(13):1190–9.

    Article  Google Scholar 

  76. Blauvelt A, Papp KA, Lebwhol MG, Green LJ, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372–4.

    Article  PubMed  Google Scholar 

  77. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159:1092–102.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12:1159–66.

    Article  CAS  PubMed  Google Scholar 

  79. Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78:70–80.

    Article  PubMed  Google Scholar 

  80. Amin M, Darji K, No D, Bhutani T, Wu J. Review of IL-17 inhibitors for psoriasis. J Dermatolog Treat. 2018;29(4):347–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Baylor Scott & White, Dallas, TX, USA

    Annika S. Silfvast-Kaiser, Dario Kivelevitch, So Yeon Paek & Alan Menter

Authors
  1. Annika S. Silfvast-Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dario Kivelevitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. So Yeon Paek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan Menter
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Silfvast-Kaiser, A.S., Kivelevitch, D., Paek, S.Y., Menter, A. (2021). Brodalumab. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation